NTRA vs. EXAS, DGX, LH, RDNT, FTRE, FMS, UTHR, RDY, UHS, and DVA
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Exact Sciences (EXAS), Quest Diagnostics (DGX), Laboratory Co. of America (LH), RadNet (RDNT), Fortrea (FTRE), Fresenius Medical Care (FMS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Universal Health Services (UHS), and DaVita (DVA). These companies are all part of the "medical" sector.
Natera (NASDAQ:NTRA) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
99.9% of Natera shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 7.6% of Natera shares are owned by company insiders. Comparatively, 1.3% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Exact Sciences received 493 more outperform votes than Natera when rated by MarketBeat users. Likewise, 72.46% of users gave Exact Sciences an outperform vote while only 68.52% of users gave Natera an outperform vote.
Exact Sciences has higher revenue and earnings than Natera. Exact Sciences is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.
Natera has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Exact Sciences has a net margin of -9.48% compared to Natera's net margin of -30.24%. Exact Sciences' return on equity of -7.12% beat Natera's return on equity.
In the previous week, Natera had 7 more articles in the media than Exact Sciences. MarketBeat recorded 23 mentions for Natera and 16 mentions for Exact Sciences. Natera's average media sentiment score of 0.76 beat Exact Sciences' score of 0.34 indicating that Natera is being referred to more favorably in the media.
Natera presently has a consensus target price of $98.47, suggesting a potential downside of 7.51%. Exact Sciences has a consensus target price of $95.40, suggesting a potential upside of 89.36%. Given Exact Sciences' higher probable upside, analysts plainly believe Exact Sciences is more favorable than Natera.
Summary
Natera and Exact Sciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Natera News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
